- January 27, 2014 @ 09:00 am
The event co-locates Phacilitate Cell & Gene Therapy Forum 2014, incorporating Stem Cells as Discovery & Research Tools, Phacilitate Vaccine Forum 2014 and Phacilitate Immunotherapy Forum 2014 We expect to welcome 500-600 attendees in total to our Washington 2014 meeting, with all networking shared and every conference session available to each attendee. PLUS delegates will receive access to an online pre-event Partnering Service, allowing them to contact individuals and organise meetings before they arrive onsite. Phacilitate Cell & Gene Therapy Forum 2014, incorporating Stem Cells as Discovery & Research Tools The Phacilitate Cell & Gene Therapy Forum celebrates its 10th Birthday in Washington, DC this coming January, 27th-29th. We will mark the occasion by delivering the biggest and best event in the series' history. Building on a record attendance in 2013 (more than 350 of the most senior decision-makers in the cell therapy, gene therapy and tissue engineered product sectors) we will welcome our largest ever speaker to the event – more than 100 of the most influential payers, regulators, investors, big pharma cheque-writers and, of course, the leading lights of the global cell & gene therapy industry itself. And brand new for 2014, we will feature a full 2-day conference stream dedicated to Stem Cells as Discovery & Research Tools, driving even more attendees from major pharma and biotech companies to the event. As in previous years, the event will be collocated with the Washington Vaccine Forum. However, this conference transforms into the Phacilitate Vaccine & Immunotherapy Forum in 2014, meaning greater synergy with the Cell & Gene Therapy Forum through dedicated coverage of cell-based immunotherapy and other therapeutic vaccine technologies. Phacilitate Stem Cells as Discovery & Research Tools 2014 This 2-day plenary conference stream (January 28th-29th) is a distinct new element of the sector-leading Cell & Gene Therapy Forum, which celebrates its 10th Birthday in Washington, DC this coming January. Stem Cells as Discovery & Research Tools is specifically designed to provide the strategic insights and networking opportunities required by senior decision makers from those companies that provide stem cell tools for drug discovery and cell banking services (plus stem cell therapy developers seeking to expand their business model), as well as the big pharma, mid-sized pharma and big biotech preclinical decision-makers who predominantly utilize them. Phacilitate Vaccine Forum 2014 The Phacilitate Vaccine Forum has set the standard for senior-level industry events for the past 13 years. And in 2014, we promise to deliver more key decision-makers from the global industry and wider community (including leading public and private sector investors, NGOs and regulators) than ever before. The conference agenda will be all-plenary this year, ensuring you don't miss out on any of the presentations and discussions. As in previous years, the event will be collocated with the well-established Cell & Gene Therapy Forum (10th Annual) and also the Immunotherapy Forum – a new event for Washington, but one that will be familiar our past Barcelona event attendees. This programme will exclusively examine therapeutic vaccines and other 'active' immunotherapeutic modalities. Phacilitate Immunotherapy Forum 2014 Phacilitate Immunotherapy Forum will be staged in Washington, DC for the first time this January, following years of success in Barcelona. We are moving the event to DC to capitalize on the significant synergies between this agenda and those for the two colocated conferences – both sector leaders in their own right: the Cell & Gene Therapy Forum (10th Annual) and the Washington Vaccine Forum (13th Annual). The conference agenda will be all-plenary, providing an invaluable strategic snapshot – as well as practical solutions – to senior-level discovers and developers of novel active immunotherapeutic modalities including checkpoint inhibitors, adoptive T-cell therapies, other cancer vaccine technologies and oncolytic virus therapeutics – in other words, the hottest emerging biopharma innovation in the world today.